USPTO serial 79434747
ASTRID
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- VAGHANI, MAYUR C
- Law office
- TMO LAW OFFICE 124
What this means
Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose. Watch for publication (status 686) and monitor the 30-day opposition window.
Need help with ASTRID?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical purposes; diagnostic preparations and materials in the nature of diagnostic reagents, diagnostic antibody reagents or antibodies, monoclonal antibodies and buffer solutions for use in in vitro diagnostics, reagents for use in in vitro diagnostics, and medical diagnostic test strips for blood analysis, all for medical and veterinary purposes; chemical, biochemical and biological preparations, namely, chemical reagents for medical purposes, biochemical reagents for medical purposes; chemical and biochemical preparations, namely, diagnostic reagents, diagnostic antibody reagents or antibodies, monoclonal antibodies and buffer solutions for use in in vitro diagnostics, and reagents for use in in vitro diagnostics, all for veterinary purposes; biological preparations, namely, diagnostic reagents, diagnostic antibody reagents or antibodies, monoclonal antibodies and buffer solutions for use in in vitro diagnostics, and reagents for use in in vitro diagnostics, all for veterinary purposes; clinical diagnostic reagents for medical use; medical diagnostic reagents and assays for testing of body fluids; diagnostic biomarker reagents for medical or veterinary purposes; diagnostic preparations for medical purposes used by medical laboratories; medical diagnostic test strips for blood analysis; diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, buffers, and reagents, for use in in vitro diagnostics, and test strips for blood analysis for disease testing; in vitro diagnostic agents for medical use; in-vitro diagnostics for veterinary purposes; diagnostic test kits for medical purposes consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents, for use in in vitro diagnostics, and test strips for blood analysis disease testing; diagnostic test kits for veterinary purposes consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for blood analysis for disease testing; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for blood analysis for disease testing for medical purposes; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for blood analysis for disease testing for veterinary purposes; medical diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for detecting acute aortic syndrome; diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for detecting aortic dissection; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostic apparatus, and test strips for detecting acute aortic syndrome; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for detecting aortic dissection; diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, monoclonal antibodies, buffer solutions, reagents and test strips for blood analysis, all for use in in vitro diagnostics for diagnosing the recurrence or progression of disease in patients following surgery; diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, monoclonal antibodies, buffer solutions, reagents and test strips for blood analysis, all for use in in vitro diagnostics for diagnosing the recurrence or progression of cardiovascular disease in patients following cardiological interventions; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, monoclonal antibodies, buffer solutions, reagents, and test strips for blood analysis, all for use in in vitro diagnostics for diagnosing the recurrence or progression of disease in patients following surgery; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, monoclonal antibodies, buffer solutions, reagents and test strips for blood analysis, all for use in in vitro diagnostics for diagnosing the recurrence or progression of cardiovascular disease in patients following cardiological interventions and surgery. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 1, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 7, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 7, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 7, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 5, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 18, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 18, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 24, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 23, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 16, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 16, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 16, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |